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Introduction
During brain development there is a strict control of the
proliferation, migration and differentiation of neural
stem cells to different cell types. Alterations in the con-
trol of these processes may result in altered balance in
the formation of different cell types resulting in a long-
lasting impairment of cerebral processes. This occurs for
example if brain is exposed to alcohol during key stages
of development which results in accelerated glial cells
formation, impaired neuron formation and impaired cog-
nitive function.
The molecular mechanisms modulating differentiation
of neural stem cells to neurons or non neuronal cells are
not well known. Nitric oxide (NO) plays a relevant role
in this process. NO increases the activity of soluble gua-
nylate cyclase and is a main modulator of cGMP levels in
brain. It has been proposed that cGMP-mediated NO sig-
nalling may be involved in the early differentiation events
of embryonic stem cells. If this is the case, pathological
situations in which the production of cGMP is altered
during brain development could lead to altered differen-
tiation of stem cells to neurons or glial cells, resulting in
cognitive impairment in the children. Moreover, normal-
izing cGMP levels in these situations could prevent the
alterations in neural stem cells differentiation and cogni-
tive impairment.
Aims
The aims of this work were to assess in rats in vivo
whether: 1) reduced cGMP levels during brain develop-
ment alters the differentiation of stem cells to neurons
or non neuronal cells in vivo; 2) reduced brain cGMP
levels during brain development leads to cognitive
impairment when the rats are young and 3) restoration
of cGMP levels prevents the alterations in neural stem
cells differentiation and in cognitive function.
Methods
To assess the role of cGMP in neural stem cell differen-
tiation we used a rat model in which brain cGMP levels
are reduced during brain development. To reduce cGMP
in brain of the foetuses we treated pregnant rats with
nitroarginine-methylester (NAME), an inhibitor of nitric
oxide synthases. We choose this treatment because, in
addition to reducing the formation of nitric oxide (NO)
and, subsequently, of cGMP, it is used as a model of pre-
eclampsia in rats. To restore cGMP levels in rats treated
with NAME, some of the rats were treated also with sil-
denafil, an inhibitor of cGMP-degrading phosphodiester-
ase. Treatment with sildenafil restores brain cGMP levels
in other pathological situations associated with reduced
cGMP in brain. Rats treated with NAME alone have
therefore deficits in NO and cGMP formations, while
rats treated with NAME and sildenafil have deficits in
NO formation but not in cGMP levels.
Results
We assessed whether the pups born from the rats trea-
ted with NAME show altered neural stem cells differen-
tiation in prefrontal cortex and cognitive impairment at
2 months of age. We also tested whether treatment with
sildenafil restores cGMP levels and prevents the changes
induced by exposure to NAME.
Treatment with NAME reduced cGMP in cerebral
cortex to 46% of control rats when the foetuses were on
gestational day 17. Co-treatment with sildenafil comple-
tely normalized cGMP in cerebral cortex.
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Reducing cGMP during brain development leads to
reduced differentiation of stem cells to neurons and
increased differentiation to non neuronal cells. In con-
trol rats 48% of the neural stem cells proliferating in
gestational day14 differentiate to neurons and 52% to
non-neuronal cells. In rats exposed to NAME only 24%
of neural stem cells differentiate to neurons and 76% to
non-neuronal cells. This alteration was substantially cor-
rected by sildenafil, in rats exposed to NAME + sildena-
fil, 40% of neural stem cells differentiate to neurons and
60% to non-neuronal cells.
Reducing cGMP during brain development also resulted
in reduced learning ability when the rats were 2 months-
old. The ability to learn a Y maze conditional discrimina-
tion task was impaired in rats exposed to NAME, which
needed 73 ± 6 trials to learn the task while control rats
needed 54 ± 3 trials. Learning ability was not impaired in
rats exposed to NAME + sildenafil or to sildenafil alone,
which needed 51 ± 3 and 55 ± 5 trials, respectively, to
learn the task.
Conclusions
These results support that cGMP modulates the fate of
neural stem cells in brain in vivo. High cGMP levels
promote its differentiation to neurons while reduced
cGMP levels promote differentiation to non neuronal
(mainly glial) cells.
Situations in which cGMP levels are reduced during
brain development result in reduced formation of neu-
rons, increased formation of non neuronal (mainly glial)
cells and impaired cognitive function. Restoring cGMP
levels normalizes neural stem cells differentiation, for-
mation of neurons and cognitive function.
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